The Competition Commission of India is expected to require certain concessions from pharmaceutical giants Ranbaxy Laboratories and Sun Pharmaceutical before they are given clearance to merge, say reports.
According to an unnamed source, the CCI will likely recommend “structural remedies” to ensure competition is not harmed from the transaction. Those remedies, reports say, may include selling assets, though neither company commented on the reports.
Sun first announced last April that it has reached an agreement with Japan-based Daiichi Sankyo to acquire Ranbaxy for about $4 billion. The companies expect to close the deal by the end of the year.
The CCI is reportedly set to send a letter to the companies suggesting its concessions; the unnamed source said the watchdog will also likely establish “a monitoring agency to ensure adherence consequent to the order.”
Full content: Business Standard
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI